GlassScriptPhysician profile
Wade Willis Muncey
NPI 1619408838
$8,957.29
in general payments reported to CMS, 2019-2025
24 companies · $1,979 in 2025
The $1,979 reported for 2025 was more than what 80% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,364 · 2020: $16.78 · 2021: $385 · 2022: $831 · 2023: $2,633 · 2024: $1,749 · 2025: $1,979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,333 · Travel and Lodging: $1,028.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,332.51 |
| Travel and Lodging | $1,028.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $3,202.70 | 2019-2025 | Ams 700 Cxr Rte Kit, Ams 700, Ams 800 Artificial Urinary Sphincter |
| Coloplast Corp | $3,000.77 | 2022-2025 | Titan |
| Endo USA, INC. | $428.62 | 2024-2025 | Xiaflex, Aveed |
| Abbvie INC. | $418.99 | 2023-2025 | |
| Endo Pharmaceuticals INC. | $361.60 | 2023-2024 | Xiaflex |
| Accord Healthcare, INC. | $222.16 | 2023-2025 | |
| Dendreon Pharmaceuticals LLC | $201.83 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $168.24 | 2024-2025 | Erleada, Balversa, Rybrevant |
| Urogen Pharma, INC. | $154.72 | 2021-2025 | Jelmyto |
| Merck Sharp & Dohme LLC | $146.54 | 2024-2025 | Lynparza, Keytruda |
| Olympus America INC. | $142.41 | 2022-2025 | Itind System |
| Baxter Healthcare | $120.71 | 2021 | |
| Pfizer INC. | $61.71 | 2024-2025 | |
| Antares Pharma, INC. | $50.00 | 2023 | Tlando, Xyosted |
| Bayer Healthcare Pharmaceuticals INC. | $47.11 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bluewind Medical | $39.31 | 2025 | Revi |
| Immunitybio, INC. | $36.40 | 2025 | |
| Blue Earth Diagnostics | $33.00 | 2025 | Posluma |
| Ferring Pharmaceuticals INC. | $30.84 | 2025 | Adstiladrin |
| Astellas Pharma US INC | $25.27 | 2025 | Veozah |
| Bioprotect Medical, INC. | $18.93 | 2025 | Bioprotect Balloon Implant System |
| Sun Pharmaceutical Industries INC. | $16.95 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $15.49 | 2025 | |
| Myovant Sciences INC. | $12.99 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wade Muncey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.